Get the Stockscreener App
0.5571
0.74%
0.0041
After Hours:
.55
-0.0071
-1.27%
Turnstone Biologics Corp stock is traded at $0.5571, with a volume of 207.46K.
It is up +0.74% in the last 24 hours and down -20.64% over the past month.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
See More
Previous Close:
$0.553
Open:
$0.5533
24h Volume:
207.46K
Relative Volume:
0.80
Market Cap:
$12.88M
Revenue:
$81.89M
Net Income/Loss:
$-55.20M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-67.40M
1W Performance:
-10.12%
1M Performance:
-20.64%
6M Performance:
-78.74%
1Y Performance:
-85.86%
1-Day Range:
$0.52
$0.5622
1-Week Range:
$0.52
$0.6375
52-Week Range:
$0.52
$5.75
Turnstone Biologics Corp Stock (TSBX) Company Profile
Name
Turnstone Biologics Corp
Sector
Industry
Phone
347-897-5988
Address
9310 ATHENA CIRCLE, SUITE 300, LA JOLLA
Turnstone Biologics Corp Stock (TSBX) Latest News
Turnstone Biologics Corp. (NASDAQ:TSBX) Short Interest Update - Defense World
Turnstone Biologics stock hits 52-week low at $0.58 amid sharp decline - Investing.com
Analyzing Organovo (NASDAQ:ONVO) & Turnstone Biologics (NASDAQ:TSBX) - Defense World
Reviewing Krystal Biotech (NASDAQ:KRYS) & Turnstone Biologics (NASDAQ:TSBX) - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.67 - Investing.com
Turnstone Biologics stock plunges to 52-week low of $0.67 By Investing.com - Investing.com Canada
Turnstone Biologics stock plunges to 52-week low of $0.67 By Investing.com - Investing.com UK
Taking on analysts’ expectations and winning: Turnstone Biologics Corp (TSBX) - SETE News
Investor’s Delight: Turnstone Biologics Corp (TSBX) Closes Strong at 0.70, Up 1.15 - The Dwinnex
Is Turnstone Biologics Corp (TSBX) a good investment opportunity? - US Post News
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Significant Increase in Short Interest - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.72 - Investing.com
Turnstone Biologics price target lowered to $10 from $12 at BofA - TipRanks
Tourmaline Bio (NASDAQ:TRML) versus Turnstone Biologics (NASDAQ:TSBX) Head-To-Head Review - Defense World
The time has not yet come to remove your chips from the table: Turnstone Biologics Corp (TSBX) - SETE News
Turnstone Biologics Corp’s results are impressive - US Post News
Turnstone Biologics (NASDAQ:TSBX) Price Target Cut to $3.75 by Analysts at Piper Sandler - Defense World
Turnstone Biologics shares target cut by Piper Sandler with no rating change - Investing.com
Turnstone Biologics shares target cut by Piper Sandler with no rating change - Investing.com Canada
TSBX’s Stock Market Adventure: -70.07% YTD Growth Amidst Volatility - The InvestChronicle
Market Momentum: Turnstone Biologics Corp (TSBX) Registers a -8.24 Decrease, Closing at 0.76 - The Dwinnex
SVB Securities slashes price target on Turnstone Biologics Corp [TSBX] – find out why. - The DBT News
Turnstone Biologics (NASDAQ:TSBX) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS - Defense World
Take off with Turnstone Biologics Corp (TSBX): Get ready for trading - SETE News
Turnstone Biologics stock plunges to 52-week low of $1.36 By Investing.com - Investing.com Canada
Why Is Turnstone Biologics Stock Trading Lower On Thursday?Turnstone Biologics (NASDAQ:TSBX) - Benzinga
Turnstone Biologics stock plunges to 52-week low of $1.36 By Investing.com - Investing.com India
Turnstone Biologics stock plunges to 52-week low of $1.36 - Investing.com
Turnstone Biologics stock plunges to 52-week low of $1.36 By Investing.com - Investing.com UK
Turnstone reports positive early trial results for cancer therapy - Investing.com
Turnstone reports positive early trial results for cancer therapy - Investing.com India
Turnstone Biologics Reports Encouraging Phase 1 Results - TipRanks
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights - ForexTV.com
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights - StockTitan
Turnstone Biologics reports Q2 EPS (92c), consensus (93c) - TipRanks
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer - StockTitan
Turnstone Biologics Corp. (TSBX): This Penny Stock is a ‘Strong Buy’ According to Analysts - Insider Monkey
Turnstone Biologics Corp. (TSBX): This Penny Stock is a ‘Strong Buy’ According to Analysts - Yahoo Finance
Turnstone Biologics Corp. (NASDAQ:TSBX) Short Interest Update - American Banking and Market News
Turnstone Biologics Corp. (NASDAQ:TSBX) Short Interest Down 20.5% in June - MarketBeat
Can you still get a good price for Turnstone Biologics Corp (TSBX) Shares at this point? – US Post News - US Post News
Investor's Delight: Turnstone Biologics Corp (TSBX) Closes Weak at 2.62, Down -12.37 – DWinneX - The Dwinnex
Can Turnstone Biologics (NASDAQ:TSBX) Afford To Invest In Growth? - Yahoo Finance
A Tale of Resilience: Turnstone Biologics Corp Amid Stock Market Turbulence - The InvestChronicle
Turnstone Biologics - The Pharma Letter
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting - Quantisnow
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference - Quantisnow
Turnstone Biologics Corp (TSBX) stock analysis: A simple moving average approach – US Post News - US Post News
Critical Survey: Turnstone Biologics (TSBX) & Its Rivals - Defense World
Reviewing Turnstone Biologics (TSBX) & Its Competitors - Defense World
Head to Head Contrast: Turnstone Biologics (TSBX) and The Competition - Defense World
Turnstone Biologics Corp Stock (TSBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):